203 related articles for article (PubMed ID: 1376779)
1. Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracil, in CCRF-CEM cells.
Romanini A; Li WW; Colofiore JR; Bertino JR
J Natl Cancer Inst; 1992 Jul; 84(13):1033-8. PubMed ID: 1376779
[TBL] [Abstract][Full Text] [Related]
2. Biomodulation of 5-fluorouracil with antifolates.
Bertino JR
Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-52-S18-56. PubMed ID: 9420021
[TBL] [Abstract][Full Text] [Related]
3. Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma.
Conti JA; Kemeny N; Seiter K; Goker E; Tong W; André M; Ragusa K; Bertino JR
J Clin Oncol; 1994 Apr; 12(4):695-700. PubMed ID: 7512128
[TBL] [Abstract][Full Text] [Related]
4. Selective treatment of SCID mice bearing methotrexate-transport-resistant human acute lymphoblastic leukemia tumors with trimetrexate and leucovorin protection.
Lacerda JF; Göker E; Kheradpour A; Dennig D; Elisseyeff Y; Jagiello C; O'Reilly RJ; Bertino JR
Blood; 1995 May; 85(10):2675-9. PubMed ID: 7742525
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxicity of trimetrexate against antifolate-resistant human T-cell leukemia cell lines developed in oxidized or reduced folate.
Miyachi H; Takemura Y; Kobayashi H; Ando Y
Jpn J Cancer Res; 1997 Sep; 88(9):900-6. PubMed ID: 9369939
[TBL] [Abstract][Full Text] [Related]
6. Implications for improved high-dose methotrexate therapeutic effects in cultured human breast cancer and bone marrow cells.
Bowen D; Southerland WM; Johnson DH; Hawkins M; Hughes DE
Cancer Detect Prev; 2000; 24(5):452-8. PubMed ID: 11129987
[TBL] [Abstract][Full Text] [Related]
7. Carboxypeptidase G2 enhances trimetrexate cytotoxicity in CCRF-CEM cell lines sensitive and resistant to methotrexate.
Romanini A; Chou TC; Bertino JR
Adv Enzyme Regul; 1989; 28():323-33. PubMed ID: 2533849
[TBL] [Abstract][Full Text] [Related]
8. Biomodulation of Fluorouracil in colorectal cancer.
Ardalan B; Luis R; Jaime M; Franceschi D
Cancer Invest; 1998; 16(4):237-51. PubMed ID: 9589033
[TBL] [Abstract][Full Text] [Related]
9. Large diversity in transport-mediated methotrexate resistance in human leukemia cell line CCRF-CEM established in a high concentration of leucovorin.
Asai S; Miyachi H; Kobayashi H; Takemura Y; Ando Y
Cancer Sci; 2003 Feb; 94(2):210-4. PubMed ID: 12708499
[TBL] [Abstract][Full Text] [Related]
10. Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study.
Punt CJ; Keizer HJ; Douma J; Skovsgaard T; Schüller J; Muller EW; Ten Napel CH; Croles JJ; Lochs H; Zhang J; Hammershaimb L
Ann Oncol; 2002 Jan; 13(1):81-6. PubMed ID: 11865814
[TBL] [Abstract][Full Text] [Related]
11. Biochemical modulation of 5-fluorouracil with or without leucovorin by a low dose of brequinar in MGH-U1 cells.
Chen TL; Erlichman C
Cancer Chemother Pharmacol; 1992; 30(5):370-6. PubMed ID: 1380407
[TBL] [Abstract][Full Text] [Related]
12. Trimetrexate: review and current clinical experience in advanced colorectal cancer.
Blanke CD; Messenger M; Taplin SC
Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-57-S18-63. PubMed ID: 9420022
[TBL] [Abstract][Full Text] [Related]
13. Sequence-dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines: implications for the mechanism of this interaction.
Sobrero A; Romanini A; Russello O; Nicolin A; Rosso R; Bertino JR
Eur J Cancer Clin Oncol; 1989 Jun; 25(6):977-82. PubMed ID: 2526736
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant sequential methotrexate --> 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer.
Sobrero A; Frassineti G; Falcone A; Dogliotti L; Rosso R; Di Costanzo F; Bruzzi P;
Br J Cancer; 2005 Jan; 92(1):24-9. PubMed ID: 15611795
[TBL] [Abstract][Full Text] [Related]
15. Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorectal cancer.
Punt CJ; Blanke CD; Zhang J; Hammershaimb L
Ann Oncol; 2002 Jan; 13(1):92-4. PubMed ID: 11865815
[TBL] [Abstract][Full Text] [Related]
16. Comparison between CoFactor and Leucovorin activity applied in combination with 5-fluorouracil against two human colon cancer cell lines.
Bjelogrlić SK; Srdić T; Radulović S
J BUON; 2007; 12(1):71-6. PubMed ID: 17436405
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity of floxuridine and 5-fluorouracil in human T-lymphoblast leukemia cells: enhancement by leucovorin.
Mini E; Moroson BA; Bertino JR
Cancer Treat Rep; 1987 Apr; 71(4):381-9. PubMed ID: 2950995
[TBL] [Abstract][Full Text] [Related]
18. A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer.
Blanke CD; Shultz J; Cox J; Modiano M; Isaacs R; Kasimis B; Schilsky R; Fleagle J; Moore M; Kemeny N; Carlin D; Hammershaimb L; Haller D
Ann Oncol; 2002 Jan; 13(1):87-91. PubMed ID: 11863117
[TBL] [Abstract][Full Text] [Related]
19. Role of methotrexate polyglutamates in methotrexate- and sequential methotrexate-5-fluorouracil-mediated cell kill.
McGuire JJ; Mini E; Hsieh P; Bertino JR
Cancer Res; 1985 Dec; 45(12 Pt 1):6395-400. PubMed ID: 2415244
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil.
Hudes GR; LaCreta F; DeLap RJ; Grillo-Lopez AJ; Catalano R; Comis RL
Cancer Chemother Pharmacol; 1989; 24(2):117-22. PubMed ID: 2525077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]